Please login to the form below

Not currently logged in
Email:
Password:

Perjeta

This page shows the latest Perjeta news and features for those working in and with pharma, biotech and healthcare.

MSD launches EU’s first biosimilar Herceptin in UK

MSD launches EU’s first biosimilar Herceptin in UK

has insisted it can ride out the storm with new products such as multiple sclerosis therapy Ocrevus (ocrelizumab) and cancer drugs Perjeta (pertuzumab), Tecentriq (atezolizumab) and Alecensa (alectinib).

Latest news

  • Roche faces biosimilar blitz in 2018 Roche faces biosimilar blitz in 2018

    Last year, Ocrevus, Tecentriq, Perjeta and Alecensa sales drove a 5% growth for Roche, along with label extensions for existing products and approvals for new medicines Ocrevus and Hemlibra in the ... US. Schwan added: “I am particularly pleased with

  • Mylan gets first biosimilar Herceptin OK from FDA Mylan gets first biosimilar Herceptin OK from FDA

    reduction in sales after the rivals launch, in part because use of the drug in combination with newer HER2 drug Perjeta (pertuzumab) is on the rise.

  • Ocrevus off to a flying start as Roche raises 2017 forecasts Ocrevus off to a flying start as Roche raises 2017 forecasts

    Perjeta (pertuzumab) for breast cancer continued to grow - rising 17% to 1.07bn francs - and immunotherapy Actemra/RoActemra (tocilizumab) also put in a good showing, rising 13% to 922m francs thanks

  • NICE relents on Kadcyla after Roche pricing negotiations NICE relents on Kadcyla after Roche pricing negotiations

    Breast Cancer Now delivered a warning about another Roche HER2 drug - Perjeta (pertuzumab) - which it said was at risk of being removed from NHS use as a first-line treatment for ... Perjeta's benefits are extraordinary, offering nearly 16 additional

  • Roche trumpets APHINITY data, but did it hit the mark? Roche trumpets APHINITY data, but did it hit the mark?

    Roche trumpets APHINITY data, but did it hit the mark? Results raise questions about benefit of combining Herceptin with Perjeta. ... A large chunk of Perjeta's $5bn sales forecast has been attributed to adjuvant use alongside Herceptin and chemo,

More from news
Approximately 16 fully matching, plus 40 partially matching documents found.

Latest Intelligence

  • Back to the future Back to the future

    In 2013, Roche's biologics sales totalled $29.2bn. These were led by established oncology brands such as Avastin and MabThera/Rituxan, along with emerging breast cancer therapies such as Perjeta

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics